Pregnancy, along with the first year after childbirth (which collectively can be referred to as the perinatal period), is arguably one of the most transformative times in a woman's life. This time frame is also a complex and vulnerable period that presents several challenges for women. In particular, an increased risk of the onset or worsening of psychiatric illness, including mood dis orders, anxiety disorders and psychosis, exists during the first 3 months postpartum. All types of psychiatric disorders can occur during the postpartum period, with many chronic disorders starting before pregnancy and persisting throughout pregnancy into the post partum period 1 . In this Primer, we focus specifically on the post partum psychiatric disorders (PPDs). Collectively, the PPDs include postpartum depression, which is rela tively common; common anxiety disorders such as general ized anxiety disorder (GAD, which can include anxieties about the health of the baby); posttraumatic stress dis order (PTSD, which can occur owing to a traumatic childbirth experience or can reflect preexisting symp toms due to previous traumas before conception or during pregnancy); and the rarer but usually severe pres entation of postpartum psychosis. Other PPDs include eating disorders (which can worsen or recur postpartum, particularly when the infant is undergoing weaning) and obsessive-compulsive disorder (OCD).
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In pregnancy, depressive and anxiety disorders are common, with recent population estimates of 11% for depressive disorders and 15% for anxiety disorders 2 . Further, antenatal anxiety and depression are two of the greatest risk factors for PPDs 3 . Inadequate social support and a history of adverse life events increase the risk of PPDs in all countries and levels of society 4, 5 . However, this risk is increased in poorer socioeconomic popula tions and lower income countries owing to poverty and limited access to health care 6 . In recent years, awareness of the potentially serious adverse consequences in both the mother and the baby associated with untreated perinatal psychiatric illness has increased. Maternal suicide due to post partum mood disorders (including unipolar and bipolar depres sive disorders) is a leading cause of maternal mortality [7] [8] [9] . In addition, perinatal mood disorders are associated with an increased risk of low birthweight and premature birth, impaired mother-infant attachment and infant malnutrition during the first year of life 10, 11 . In this Primer, we focus on maternal PPDs, as they are common, morbid and have a growing literature on the underlying pathophysiology. These disorders should not be confused with the socalled baby blues, which are usually described as transient, mild mood and anxiety symptoms that often persist for ≤2 weeks and usually resolve spontaneously with no sequelae 12 . If the symptoms of the baby blues worsen and/or persist, they are consid ered PPDs. Herein, we discuss the epidemiology of PPDs and their underlying mechanisms and pathophysiology. We mainly focus on maternal PPDs, although pater nal disorders are mentioned in some instances
. Importantly, we review the latest evidence on the diag nosis, screening and prevention as well as management of PPDs. Last, we hope to put in context the public health effect of these disorders on mothers, their children and families, to encourage widescale adoption of strategies that make maternal mental health a global priority Epidemiology Data on the incidence of postpartum depression are from studies conducted in countries across the world, and different incidence and prevalence values are reported between countries 14 . By comparison, studies estimating the incidence and prevalence of post partum psychosis are primarily carried out in Europe 15 and demonstrate less variability in the reported incidence and preva lence 16, 17 . Several methodological factors have influ enced these differences 18 . For example, particularly for post partum depression, the definition of the post partum period varies between studies and has been defined as up to 4 weeks, 3 months, 6 months or 12 months post partum 19 . Differences in study designs, such as using different tools to define case groups and phenotypes, can lead to variability in the reported number of cases. Data sources for postpartum depression and post partum psychosis include selfreports and interviews, in addition to some populationbased register data 16 . Moreover, the incomplete availability of longitudinal data that are needed to distinguish between firsttime and recurrent psychiatric episodes might impede calcu lations of the true incidence and prevalence of PPDs. Consequently, variations in the reported incidence and prevalence could be due to differences in methodologies between studies, which make direct comparisons diffi cult. In addition, the diverse symptoms of PPDs pose specific challenges to the estimation of the prevalence and incidence of these disorders 20 .
As the literature surrounding the epidemiology of PPDs continues to grow with welldesigned studies, we will have a better understanding of whether differ ences in the incidence and prevalence of postpartum depression and postpartum psychosis are due to local, regional or national differences, or whether the differ ences are due to the different study designs and data sources. This knowledge will assist in the generation of hypotheses that might provide clues for the aetiology of these disorders.
Mood disorders and anxiety
Postpartum depression, comprising major depressive disorder and subthreshold depression, has an estimated point prevalence of 13% in highincome countries 11 and ~20% in lowincome and middleincome countries 3 months postpartum 21 
. In women with a history of any eating disorder, the prevalence of post partum depression has been estimated at 35% 22 . Studies of postpartum depression often rely on selfreport ques tionnaires, including the commonly used Edinburgh Postnatal Depression Scale (EPDS) 14, 23 . Although the prevalence estimates for postpartum mood disorders range between studies, guidelines are available that state that these disorders pose substantial public health risks and, consequently, must be identi fied and treated 24, 25 . Moreover, there is consensus that childbirth is a strong and potent risk factor for bipolar dis order. Indeed, the risk of underlying bipolarity in firstonset depression occurring in the postpartum period is higher than the risk in firstonset depression occurring outside of the perinatal period. In addition, women with bipolar disorder have a high risk of post partum episodes, including depression, anxiety, mania and psychosis 26, 27 . The estimated prevalence of postpartum anxiety dis orders is ~10%, with a prevalence of 6% for GAD 28 . Anxiety disorders have substantial comorbidity with post partum depression and other disorders, includ ing postpartum PTSD, eating disorders and the exacerbation of personality disorders 17 .
Postpartum psychosis
The onset of a severe mental disorder requiring acute inpatient psychiatric treatment in the first postpartum months occurs after ~1 in 1,000 childbirths [29] [30] [31] [32] , and these disorders are considered some of the most severe forms of illness in psychiatry 18 . These severe psychiatric dis orders that onset in the immediate postpartum period are often called postpartum psychosis, which is an umbrella term for disorders recorded as, for example, mania, mixed episodes, psychotic depression or psychosis not otherwise specified 33 . Women with bipolar disorder have the highest risk of postpartum psychosis compared with women with other psychiatric diagnoses, as the risk of postpartum relapse in women with bipolar disorder is on average 37% 18 . However, variations also occur within bipolar disorder, as the risk of a severe episode is greater for women with bipolar I disorder than for women with bipolar II disorder 34 . Additionally, the risk of symptom recurrence is particularly high for women with bipolar disorder who are not receiving medication during preg nancy 18 . Relapse of psychosis can also occur in women with other psychiatric disorders, such as schizophrenia, although this is less common 35 (~16% within the first 12 months postpartum) and manifests differently than in women with bipolar disorder 16 . Despite the widespread use of the term postpartum psychosis, this diagnosis is not recognized in current classification systems, including both the International Classification of Diseases, Tenth Revision (ICD10) and the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM5) 36 . However, psychotic episodes are more prevalent during the post partum period than during other periods in a woman's life, and evidence clearly suggests a particular vulnerability in women with bipolar disorder 29 .
Box 1 | Paternal postpartum depression
Fathers can also experience depression after the birth of a child. Indeed, in men, the prevalence of depression after the birth of a child is greater than at other times during life 240 . Although the literature on paternal depression is much smaller than that for maternal depression, the available literature demonstrates that paternal depression increases the risk of long-term adverse outcomes in the child owing to potential impairments in parenting 241, 242 . In addition, a strong link between maternal depression and paternal depression has been reported. Pregnant women who had partners with depression during their pregnancy had a worse severity of depression symptoms during the first 6 months postpartum 243 . Thus, including fathers in health assessments during the postpartum period and screening fathers for postpartum psychiatric disorders at similar time intervals as maternal screening are important. Efforts aiming to improve the overall health and functioning of the family unit will lead to the best outcomes for the child 240, 242 .
In women with severe postpartum psychiatric ill ness, maternal suicide is often a predominant concern. Although maternal suicide is a leading cause of mater nal mortality 7 , the rates of completed suicide in post partum women are lower than those in agematched women without children 37 . Nonetheless, the preven tion of maternal suicide is paramount and requires careful monitoring during the postpartum period and possibly extending beyond the first year after child birth. For example, one study demonstrated that most suicides in the post partum period occurred between 9 and 12 months post partum and that the perinatal suicides were by highly lethal means (such as via firearm), suggest ing that limiting followup to 1, 3 or 6 months postpartum is insufficient 38 .
Mechanisms/pathophysiology
As previously mentioned, childbirth is one of the most potent triggers of psychiatric illness. Given that post par tum mental health disorders are one of the few occurren ces in psychiatry whereby a biological trigger occurs at a known time point, elucidating the patho physio logy of these disorders might shed light on the mechanisms of mood and psychiatric disorders more broadly and is vital for developing new treatment approaches.
The aetiology of all psychiatric disorders, including PPDs, is a complex interaction of psychological, social and biological factors, including the effect of genetic and environmental influences on risk 12 (FIG. 1) . The involvement of particular aetiological factors differs between PPDs 34 ; for example, biological factors might have a greater role in the triggering of postpartum psychosis, whereas psychosocial factors might have an important contribution in postpartum depression 34 . These factors and their involvement in different PPDs are areas of intense investigation, and future research is needed to improve our understanding of the many ways that psycho logical and biological processes inter act. Stopping or changing medications in women with a prior history of psychiatric disorders owing to concerns about the safety of medication during pregnancy could be considered a simple explanation for the triggering of PPDs. Conversely, continuing medication in pregnancy is protective against mood disorders in only a subset of patients 39 . Similarly, discontinuation of medication does not guarantee that women will relapse 40 . However, much is still not understood about PPDs, and the onset of PPDs reflects the outcome of many different pathways that manifest in women at risk. Future research will need to identify the mechanisms of depression in women before, during and after pregnancy to increase our understand ing of the similarities and differences between perinatal depression and depression occurring at other times in life. Current theories of the psychosocial and biological contributions that increase the risk of PPDs are discussed in the following sections.
Box 2 | Postpartum mental illness in low-income and middle-income countries
In resource-poor settings, women of reproductive age typically have socioeconomic and health challenges that interplay in mutually reinforcing ways 244, 245 . For example, low levels of education, low gender status, food insecurity, high levels of domestic abuse and lack of access to social and health services leave women and girls vulnerable to maternal mortality and chronic morbidities, including common mental health disorders 246, 247 . Indeed, the prevalence of common perinatal mental disorders in low-income and lower-middle-income countries is higher than in high-income countries. One systematic review and meta-analysis demonstrated a weighted mean prevalence of 15.6% in pregnant women and 19.8% in women after childbirth 21 . The most strongly associated factors are socioeconomic disadvantage, unintended pregnancy, younger age, unmarried status, lack of intimate partner empathy and support, hostile in-laws, partner violence, insufficient emotional and practical support, a history of mental health problems and, in certain settings, a female baby 21 .
Considerations for management
Mental health prevention and treatment investments in high-income countries are more than US$50 per year per person, whereas they are less than $2 in most low-income and middle-income countries (LMICs) 248 , resulting in a profound paucity of mental health providers in these lower-income settings. The intervention coverage for common mental disorders, including those that occur during the perinatal period, ranges from 7% to 28% in LMICs 249 . The low monetary allocation represents, in part, a poor appreciation by decision makers of the effect of mental illness on population disability and socioeconomic development, low levels of political will and capacity and competing health and development priorities 250 . Interventions that are most likely to succeed in LMICs would, therefore, need to adopt a systems-strengthening, integrated and low-cost approach. Examples showing promise have integrated mental health into primary care, maternal and child health services or into the routine community-based delivery of health services (carried out by trained lay workers or primary care health workers using a task-sharing approach) 251 . Emerging evidence supports the benefit of including poverty alleviation strategies in mental health interventions 252 .
Types of interventions
A systematic review and meta-analysis of evidence of common perinatal mental disorder trials from LMICs reported similar relative risk outcomes as those identified in studies carried out in high-income countries 253 . For the 13 trials selected, the pooled effect size for maternal depression was −0.38. In this review, trials that demonstrated positive results used several culturally adapted treatment paradigms, either singly or in combination. For example, the Thinking Healthy Programme in Pakistan was a cognitive behavioural therapy intervention delivered in homes in a semi-rural setting by Lady Health Workers 254 . Uptake of the intervention leveraged the belief, within multigenerational households, that intervention with the mother would improve the infant's well-being. In an urban, disadvantaged setting in Chile, midwives and nurses were trained to deliver eight weekly structured psychoeducational group sessions. These sessions included information about symptoms and treatments, some problem-solving strategies, behavioural activation strategies (such as scheduling pleasurable activities) and some cognitive techniques using postnatal examples 255 . Subsequently, a trial in Zimbabwe used peer counsellors to deliver 6 weeks of group problem-solving therapy adapted for the local setting to postnatal women with depression 256 . In this study, family members were co-opted to support the mothers through strategies identified in the problem-solving sessions, and a specific treatment element that explored community resources and support systems was included. 6 weeks after the intervention, the decrease in mean Edinburgh Postnatal Depression Scale score was greater in the problem-solving therapy group than in the control group, which received antidepressant therapy. No difference in outcomes between women with and without HIV was reported.
Psychosocial factors and comorbidities
Psychological and social stressors contribute to the devel opment of maternal PPDs and are associated with poorer outcomes in infants or children 41, 42 . In particular, adverse life events and a history of trauma have a higher preva lence in women who develop postpartum mood dis orders compared with women who develop mood disorders outside of the perinatal period 4, 43, 44 . A history of adverse early life experiences can substantially affect a mother's ability to have a strong attachment with her infant 45 , and adverse parent-infant interactions and worse attachment are associated with the development of PPDs [46] [47] [48] . Social support has a vital role in either contributing to or mitigating the effect of postpartum mood dis orders on both the mother and child 49 . Indeed, social support, or the degree of tangible support provided from the social network of the mother and from the part ner (such as financial support or assisting with infant care), has the greatest effects on postpartum depression compared with many other psychosocial risk factors 50 . Other psychosocial risk factors include a past his tory of a mood disorder, which is consistently associ ated with an increased risk of postpartum depression and postpartum psychosis 34 . Although the strength of the association between risk factors and PPDs varies between highincome countries and lowincome and middleincome countries, one of the strongest psycho social risk factors in both settings is domestic violence and a history of abuse, including abuse during child hood 4, 51 . Other risk factors with a mediumtostrong association with PPDs include marital difficulties, migration status and antenatal depression or anxiety 17, 52 . In addition, poverty, young age (between 14 and 21 years of age), substance misuse, increased parity, multiple births, an unwanted pregnancy, neuroticism, pregnancy complications, obesity and comorbidities (for example, diabetes, hypertension and preeclampsia) and neonatal problems are associated with PPDs 17 .
Genetic factors
Data from twin and adoption studies have implicated genetic factors in the aetiology of psychiatric disorders outside of the perinatal period, including schizophrenia and mood disorders 53, 54 . However, only recently have genetic investigations of PPDs, primarily of postpartum depression and postpartum psychosis, been conducted.
Genetic epidemiological and linkage studies for postpartum depression have demonstrated the role of genetic factors [55] [56] [57] , and two studies have demonstrated the increased heritability of postpartum depression com pared with depression outside of the perinatal period 58, 59 . To date, studies have suggested that episodes of post partum psychosis are a marker for a morefamilial form of bipolar disorder and that the puerperal triggering of bipolar illness is familial 60, 61 . However, a genomewide association study using modern genomics methods has not yet been carried out for either postpartum depres sion or postpartum psychosis. Future genetic studies of postpartum mood disorders using modern genomic methods will require international collaborations and consortia to include a large number of patients; these studies are currently underway 62, 63 . Psychological stressors and early life adverse events have a lasting negative effect and can result in patho physio logical changes and altered gene expression owing to increased allostatic load (the cumulative stress on the body that is a sum of an individual's lifetime expo sure to stress) 64 . Potential mechanisms underlying how stressful life events change gene expression include epi genetic modification (such as DNA methylation and his tone modification that changes DNA accessibility and chromatin structure) 65 , changes in the transcriptional control of stressresponsive pathways 66 and shortened telomere length 67, 68 . Epigenetic alterations have been demonstrated in two genes, HP1BP3 and TTC9B, which have different methylation patterns in women with post partum depression depending on whether the mood symptoms begin during pregnancy and continue into the postpartum period or whether the symptoms develop in the postpartum period only 69, 70 . These data indicate that different patterns of gene expression might arise based on the timing of symptom onset. However, these findings require replication, and overall, the mechanism of action in postpartum depression remains to be established. 
Sleep disruption
An almost universal feature of pregnancy and child birth is sleep disruption. In addition, sleep and circadian rhythm disruption can trigger the onset of psychiatric disorders in the postpartum period, particularly epi sodes of mania 71, 72 . Thus, the fact that circadian rhythm disruption has not received more attention as a potential mechanism of PPDs is surprising.
Numerous studies have demonstrated substantial changes in maternal sleep patterns during the peri natal period. Pregnant women have poorer subjective sleep quality, increased waking and more sleep-wake transitions than women who are not pregnant 73 . In the postpartum period, new mothers have frequent night waking, decreased nighttime sleep, increased daytime napping and a more irregular sleep-wake schedule, which is speculated to increase the risk of PPDs 74 . The mechanisms underlying the disrupted maternal sleep patterns in the perinatal period have been reported in two crosssectional studies. The first study demonstrated a blunted melatonin amplitude in postpartum women compared with women who were not pregnant 75 , and the second study demonstrated differences in circadian rhythms between perinatal women with depression and perinatal women without depression; indeed, in the second study, women with depression had clinically signifi cant circadian rhythm phase shifts 74 . Further research is needed to better understand the mech anisms of sleep disruption that might trigger PPDs and potential interventions that target the circadian rhythm disruptions during the perinatal period 76 .
Reproductive hormones
One important hypothesis regarding the aetiology of PPDs is based on the temporal onset of these dis orders immediately after childbirth, which is a time of major physiological change for women, including alter ations in hormonal systems. Multiple lines of evidence have demonstrated that fluctuations in reproductive hormones during the perinatal period are substantial contributors to the development of postpartum mood disorders in women at risk. Gonadal steroid hormones (such as oestrogen and progesterone) are produced at very high levels during pregnancy but rapidly decrease to prepregnancy levels after childbirth. One study simu lated this pattern of hormone expression and demon strated substantial mood symptoms (such as sadness, anhedonia and anxiety) during the withdrawal period in five of eight women with a history of postpartum depres sion but in none of the eight women without a history of postpartum depression 77 . Thus, women who are vulner able to postpartum psychiatric episodes might not have gross abnormalities in endocrine physiology (such as no differences in the absolute levels of hormones) but might have an abnormal response to the hormonal fluctuations of pregnancy and childbirth.
Reproductive hormones have important functions in the central nervous system. Oestrogen and proges terone receptors are expressed throughout the brain and can modulate neurotransmission and neuroplasti city via both genomic and nongenomic mechanisms.
For example, brainderived neurotrophic factor (BDNF) levels in the hippocampus and the forebrain of rodents are reduced by ovariectomy and increased by oestra diol administration 78 , and BDNF levels are decreased by stress and depressive symptoms and are increased following antidepressant use in patients with depres sion 79 . The rapid fall in oestrogen levels in the post partum period might, therefore, reduce BDNF levels and increase susceptibility to PPDs in women at risk. Similarly, progesterone has an important role in regu lating neurotransmitter synthesis, release and transport 80 and has been shown to upregulate BDNF expression in the hippocampus and cerebral cortex in rodent models 81 . The neurosteroid allopregnanolone, which is a major metabolite of progesterone, might also have an impor tant role in the aetiology and, potentially, in the treat ment of postpartum depression 82, 83 . Allopregnanolone is a positive allosteric modulator of synaptic and extra synaptic γaminobutyric acid type A (GABA A ) receptors 84, 85 , and intravenous allopregnanolone admin istration significantly reduces anxiety and depressive symptoms in animal models 86 . Allopregnanolone concentrations reach peak physiological levels during the third trimester of pregnancy and rapidly decrease follow ing childbirth 87, 88 . The failure of GABA A receptors to adapt to the rapid fluctuations in allopregnanolone levels at childbirth is hypothesized to be a trigger for postpartum depression 89, 90 . This hypothesis is being explored by the development of brexanolone (a propri etary formulation of allopregnanolone) as a treatment for postpartum depression 91, 92 . Oxytocin is a neuroactive hormone that supports childbirth, lactation, maternal behaviour and social bonding 93 . An inverse association between circulating oxytocin levels and postpartum depression has been demonstrated in some studies 94 , although other studies have not found this association 95 . The alterations in the oxytocin system that occur during pregnancy and child birth do not occur in isolation, and the role of oxytocin in postpartum depression is likely to be complex and not accounted for by absolute levels, similar to the roles of other neuroactive hormones 83 . Further, recent neuroimaging data increase our understanding of the neurobiological basis under lying perinatal mood disorders and the development of maternal behaviour. For example, the effects of a poly morphism in BDNF (BDNF Val66Met) on hippo campal function are selectively modulated by oestradiol 96 . This work lends further support to the importance of the role of sex steroids in the regulation of behavioural functions associated with psychiatric disorders, such as emotional processing, arousal, cognition and motiv ation. Accordingly, the involvement of sex steroids on brain function could be revealed using neuroimaging. Indeed, multiple cortical and subcortical brain regions have altered activity that can be observed using func tional MRI or PET (such as measurement of brain mono amine oxidase type A 97 ) in mothers with depres sion in response to infant and noninfant emotional cues 98, 99 . These alterations might affect important neuro nal networks that are associated with learned reward, reaction to stimuli, stress, motivation and executive functioning. In addition, distinct neurobiological pat terns that distinguish anxiety and depression occurring in the perinatal period compared with other times of a woman's life have been observed using functional MRI, and these patterns might have a significant effect on the mother-infant relationship 100 .
Other factors Stress axis. The postpartum period is a time of great flux for the hypothalamic-pituitary-adrenal (HPA) stress axis 101 . Indeed, several alterations in the HPA axis occur during pregnancy, such as corticotropin releasing hormone production by the placenta, result ing in significantly increased levels during pregnancy, which abruptly decline postpartum 102 , and rising levels of gonadal steroids that contribute to puerperal hyper trophy of the pituitary and adrenal glands, leading to increases in adrenocorticotropic hormone and cortisol levels 103 . Corticotropinreleasing hormone fluctuations during the perinatal period might trigger HPA axis dysregulation and contribute to the onset of depressive and anxiety symptoms in a subset of women at risk 104 ; however, inconsistent findings have been reported 105, 106 .
Thyroid hormones. Thyroid hormones have been impli cated in the development of postpartum mood disorders. Thyroxinebinding globulin (TBG, which transports thyroid hormones in the blood) concentrations increase during pregnancy and might be an index of sensitivity to elevated oestrogen levels. Decreased TBG levels have been suggested as a predictor of perinatal depression in some studies 107 . In addition, firstonset postpartum autoimmune thyroid disorders often cooccur with postpartum mood disorders 108 . The occurrence of both disorders coincides with the postpartum rebound phenom ena of the maternal immune system, suggesting an overlap in aetiology 109 . Supporting this hypothesis, women with increased thyroid peroxidase antibodies during pregnancy have an increased risk of postpartum psychiatric episodes 109, 110 . Accordingly, the assessment of thyroid function (such as the measure ment of thyroid stimulating hormone levels, tri iodothyronine (T3) and tetraiodothyronine (T4)) is an essential part of diagnostic evaluations in women with postpartum psychiatric episodes.
Neuroimmune pathways. Neuroimmune pathways might also have a role in the pathophysiology of post partum mood disorders 101, [111] [112] [113] . The transition from pregnancy into the postpartum period is characterized by an accelerated immune response (mediated through both proinflammatory and antiinflammatory medi ators for healing and involution) during labour that con tinues into the early postpartum period 114 . Consequently, immune changes at the end of pregnancy might predict postpartum depression. IL6 levels are increased in women with postpartum depression compared with postpartum women without depression in some but not all studies 112, 115 . However, leptin (a protein hor mone made by adipose cells that regulates energy and has inflammatory functions) might also be associated with postpartum depression. Indeed, decreased maternal serum leptin levels during delivery are associated with a higher risk of postpartum depression and might poten tially serve as a biomarker for this disorder 115 . Lower levels of uteroglobin (also known as CC16, an endo gen ous antiinflammatory compound) during preg nancy are associated with PPDs a few weeks later 116, 117 . Further more, decreased levels of ω3 polyunsaturated fatty acids (PUFAs) at the end of the third trimester are suggested to be associated with an increased risk of PPDs in the early postpartum period 118 . The underlying mechanism is hypothesized to be increased peripheral inflammation 118 owing to the antiinflammatory effects of ω3 PUFAs. In summary, dysregulation of the cross talk between the immune system and the HPA stress axis is hypothesized to be associated with the onset of postpartum depression 101, 119 . Interestingly, first pregnancies are more often fol lowed by psychiatric episodes than subsequent preg nancies, which might illustrate the dysregulation of psychoneuroimmune systems. This effect is hypoth esized to be due to the biological differences between first and subsequent pregnancies and has raised the pos sibility of an aetiological link with other medical condi tions that have a higher prevalence in first pregnancies, such as preeclampsia 120 . Intriguingly, preeclampsia and postpartum psychosis are both associated with immune dysregulation, as demonstrated by, for example, the increased rates of postpartum autoimmune thyroid itis 108, 109 and alterations in immune biomarkers (such as central nervous system autoantibodies) in women with postpartum psychosis 121 . In addition, abnormalities in monocyte and T cell function and tryptophan break down have been demonstrated in women with post partum psychosis or mania compared with postpartum women without any psychiatric symptoms 122 . Patients with postpartum psychosis had monocytosis and failed to demonstrate the physiological T cell increase that is normally observed during the postpartum period. These findings support the notion that immune system dys regulation contributes to affective instability and severe postpartum episodes 122 . Future studies are needed to extend our understand ing of the ways in which psychological and biological processes interact in PPDs. For example, social sup port might exert a stressbuffering effect via the down regulation of stress responses, including inflammatory reactiv ity to stressors and dampened sympathetic and HPA axis activity 123, 124 .
Diagnosis, screening and prevention
As with all psychiatric disorders, the diagnosis of post partum depression is reached by a comprehensive clin ical interview and diagnostic criteria that provide an operationalized definition of the disorder, using classifi cation systems such as the DSM5 (REF. 125 ) or ICD10
(REF. 126 ). Diagnostic criteria are similar across the DSM5 and ICD10, which are the two most common classifi cation systems; however, the DSM5 uses the term 'depression with peripartum onset' to refer to the onset of depression during pregnancy and into the first month postpartum, whereas the ICD10 does not use a primary code referring to the perinatal period, although a secondary code denoting postpartum onset is available (which is not used in practice). However, the diagnosis of psychiatric disorders is more than a list of symptoms and the effect of symptoms on function ing; diagnosis should also include an understanding of predisposing aetiological factors, triggers and mainten ance factors, which are elicited by a comprehensive biopsycho social assessment 24 . Postpartum depression is one of the most common PPDs and can be mild and relatively selflimiting, lasting only a few weeks, or can be more severe, with severe epi sodes potentially including psychotic symptoms 17 . Some symptoms of depression, such as fatigue, sleep distur bance and appetite disturbance, need careful inquiry, as a woman with a baby will be more tired than usual and will have disrupted sleep (owing to the baby need ing to feed), although appetite might not be affected as breastfeeding will stimulate appetite despite a low mood. Checking whether the mother is able to sleep when the baby is asleep, whether the fatigue persists after rest and the mother's interest in food will help to establish whether the symptoms are pathological and whether they are indicative of postpartum depression. Notably, anxiety might be a prominent symptom in postpartum depression 63 or can be a symptom of a comorbid anxiety disorder 127 . Diagnostic assessment should evaluate for a history of manic or hypomanic symptoms, as firstonset postpartum depression can indicate underlying bipolar disorder 26 . Diagnostic challenges include barriers to dis closing symptoms due to stigma 128 and variations in the manifestation of symptoms, which might reflect cultural or educational differences 129 . In addition, ensuring that symptoms are not due to an underlying medical condi tion such as thyroid disease or an early presentation of first episode psychosis is important.
Although postpartum psychosis is not included as a primary diagnosis in the DSM5 or ICD10, this dis order is still recognized clinically and is usually consid ered a severe mood disorder 16 . Women with postpartum psychosis often have a history of bipolar disorder 16 . Most women have prodromal symptoms before the overt onset of postpartum psychosis; however, some women have acute onset of severe symptoms 130, 131 . Evaluating women with postpartum psychosis includes assessing manic, depressed, anxious and psychotic symptoms and the risk of the mother causing harm to herself or her baby. Women with postpartum psycho sis can present with either low or high mood (both elation and irritability) or frequently can present with a mixed state, including symptoms of both mania and depres sion; a minority of women have an atypical symptom profile with disorientation and/or disturbance of con sciousness 132 . Symptoms can also manifest as delusions, hallucin ations and, particularly, confusion and per plexity, and patients can also have severe mood swings, insomnia, agitation and rapid deterioration. Postpartum psychosis is usually a rapid onset, severe psycho sis, typically starting within the first 2-4 weeks after childbirth, and is considered a psychiatric emergency as a lack of selfcare, and an inabil ity to care for the infant can lead to suicide and/or, in rare cases, infanti cide 16 . Accordingly, assessment should be carried out quickly (for example, The National Institute for Health and Care Excellence (NICE) recommends assessment within 4 hours of clinical presentation; in clinical prac tice, this means within 24 hours of the acute onset of severe psychiatric symptoms) to ensure the woman can be cared for safely and appropriately. Excluding other medical disorders, such as cerebral spaceoccupying lesions, thyroid disorders or infections, is important as part of the diagnostic workup. In many cases, the mother's partner or family asks for psychiatric evalu ation when the mother is irritated or agitated and not aware that she is seriously ill.
Anxiety disorders (such as GAD and panic dis order), OCD and PTSD can all manifest in the postpartum period. OCD is characterized by obsessive thoughts. Obsessions are intrusive, repetitive thoughts, images or impulses that are unacceptable and/or unwanted and give rise to subjective resistance. By contrast, the delu sions that occur in psychotic disorders are fixed, false beliefs 133 that need appropriate psychological interven tion 17 . Postpartum OCD poses a particular diagnostic challenge as intrusive thoughts about harm befalling the infant (such as 'what if I drop my infant?' or 'what if I accidently cut the infant with a knife when I'm cook ing?') might be perceived as delusions and could lead to concerns about the safety of the infant. However, these thoughts are not associated with actual direct harm, and the obsessions remain very egodystonic and highly distressing for the patient. Traumatic childbirth experiences can trigger PTSD, particularly in women with prior histories of trauma 134 . Differentiating the exacerbation of PTSD symptoms in women with past trauma from newonset PTSD owing to traumatic child birth is important 135 . Past trauma history should include assessing prior childhood abuse and adult interpersonal or other violence, among other forms of trauma. In addi tion, many women with PTSD or OCD present with symptoms of anxiety and mood symptoms, making the diagnosis of one particular disorder a challenge 63, 136 . Women with a previous history of psychiatric dis orders will often experience a worsening of symptoms during the postpartum period, although few studies have examined strategies to mitigate this exacer bation 9 . For women without a prior history of psychiatric dis orders, the acute onset of psychiatric symptoms in the postpartum period is often highly distressing. However, whether the first onset of psychiatric symptoms dur ing the postpartum period indicates the beginning of a more persistent and chronic mood disorder or whether the condition will be restricted only to the post partum period is unclear. This is an important area for future study.
Screening
Screening for postpartum depression has attracted wide spread interest from researchers, clinicians and policy makers owing to the high prevalence and associ ated sequelae in terms of maternal morbidity and adverse child outcomes of this disorder. In many countries, screening for postpartum depression during routine obstetrical care, including care by health visitors, is inconsistent, and this strategy has become an area of focus in many countries. In addition, up to 60% of women with perinatal depression do not seek help 137 . However, given the availability of screening instru ments and effective treatments 138 , clinical practice guide lines and recommendations are increasingly supportive of routine screening 139, 140 . More generally, international guidelines reflect a consensus that improved identifi cation of PPDs is vitally important 24, 141 . Accordingly, several national campaigns to increase awareness of PPDs are underway, such as the Maternal Mental Health Alliance 142 in the United Kingdom. This alli ance is a coalition of organizations that are dedicated to achieving consistent, accessible and quality mental health care in the first year after giving birth. In addi tion, state mandates for perinatal depression screening are increasing in the United States, including in the US Preventive Services Task Force recommendation 140 . However, although this task force has concluded that the evidence base is sufficient to recommend screening for perinatal depression when combined with adequate sup port systems 25, 140 , this conclusion has also been criticized by others 143 . The most widely researched and used screening tool for postpartum depression is the brief tenitem EPDS 144 , which was designed to exclude symptoms that can be normal features of the perinatal period, such as poor sleep, but that are often included in other selfreported measures. A cutoff score of 13 is most commonly used to recommend further diagnostic assessment 145, 146 . In addition, the EPDS includes questions about thoughts of selfharm, which can help to mobilize risk assessment and can predict suicidal intent 147 . The EPDS has been used prenatally and validated in a number of languages, the properties of this screening tool are relatively well understood 146 , and it appears to be easy to use and accur ate in the target population 148, 149 . High EPDS scores can reflect several psychiatric diagnoses. For example, among 826 women who screened positive out of 10,000 women, the most common primary diagnosis was uni polar depressive disorder (found in 68.5% of women), but almost twothirds of women had comorbid anxiety disorder, and 22.6% had bipolar disorder 150 . These data highlight another potential benefit of the EPDS: most women with a falsenegative result for unipolar depres sion have another diagnosable, and potentially treatable, psychiatric condition.
Other generic or perinatalspecific depression measures have been used to identify perinatal depres sion but are not as well validated in perinatal women as the EPDS. Other measures include the Postpartum Depression Screening Scale 151 24, 155, 156 ) can be asked to women to determine whether further mental health assessment should be carried out, and the use of these questions is recommended by the NICE guidelines in the United Kingdom. The Whooley questions can also be used to detect any psychiatric disorder and are not limited to depression 2 . As previously mentioned, postpartum depression is frequently comorbid with anxiety (in 4.3% of women). Anxiety substantially affects maternal functioning and fetal and infant development 28, 127, 157 , which has spurred efforts to screen for postpartum anxiety. Three subitems of the EPDS (the socalled EPDS3A) can be used to identify perinatal anxiety disorders and sub syndromal anxiety 158 . Other screening instruments for anxiety disorders include the Perinatal Anxiety Screening Scale 159 and the GAD7 (REF. 160 ). Screening tools for peri natal OCD and PTSD are also available, such as the speci fic Perinatal Obsessive-Compulsive Scale 161 and SPAN, respectively 162 . The utility of routine screening for postpartum psycho sis, hypomanic and manic symptoms and bipolar disorder faces several barriers, including a lack of evi dence of effectiveness and the reduced predictive value of screening for a relatively rare condition. Despite steady progress in this area 163, 164 , a consensus test with wellknown precision and an agreed cutoff has not been identified 165, 166 . However, the Mood Disorder Questionnaire has shown solid psychometric properties for assessing bipolar disorder and is increasingly used 167 . Taking a full personal and family history might help to identify vulnerability to bipolar disorders, which could trigger further diagnostic assessment, given the strong association between bipolar disorder and increased risk of PPDs 24, 141 . In general, screening programmes for PPDs should include a clear pathway from screening to diagnostic assessment and treatment 168 . Best practice guidelines agree that all women who screenpositive need subse quent assessment, during which comorbidities and the woman's wider psychosocial context can be explored. Currently, only such wellresourced, integrated manage ment programmes have provided evidence that perinatal mental health is improved by depression screening 169, 170 . In this regard, escreening and etreatments to facili tate integrated, costeffective care might be useful 171 . Few wellunderstood, validated screening approaches for PPDs that can ultimately improve morbidity and mortality are available. Indeed, improving the evidence base for screening, including the cost effectiveness of perinatal depression screening as a policy direction, is required 141, 172 .
Prevention
Interventions for the prevention of postpartum depres sion or postpartum anxiety are intended to prevent the onset, duration or recurrence of these disorders. Prevention can reduce the mental health, physical health and socioeconomic burden associated with postpartum depression for mothers, their offspring and families, and for health systems. The effectiveness of prevention of postpartum depression is facilitated by the fact that preg nant women are motivated to address factors that will affect their baby 173 . The assessment of risk factors for PPDs helps with diagnosis and formulation but is also important for identifying potentially modi fiable targets for prevention and treatment 174
. Thus, systems for adequate followup and support after both symptom screening and risk assessment are required. Furthermore, women and clinicians should be informed that the established risk factors might have limited pre dictive value for individual patients and, therefore, do not guarantee which women will develop or not develop postpartum depression.
Some psychosocial and psychological interventions have reduced the risk of women developing post partum depression, although no single intervention type or modality is superior to others. Data from trials included in a Cochrane review 174 as well as randomized controlled trials included in a qualitative review 173 point towards particularly positive effects when interventions target atrisk groups (such as women with a previous episode of depression or a recent life stressor) or include inter personal therapy (IPT). As relationship challenges and lack of social support constitute strong risk factors for PPDs, the interpersonal focus of IPT aims to address this causative or aggravating factor. Trials included in these reviews were conducted among women at high risk on the basis of various factors, as well as women enrolled from the general perinatal population.
Trials assessing the use of IPT, peer support, paren tal preparedness and personcentred approaches for the prevention of postpartum depression have demonstrated significantly positive results, whereas trials assessing the use of cognitive behavioural therapy (CBT) for post partum depression have demonstrated mixed results. These results, disaggregated for universal, selective or indicated prevention strategies, are summarized in a more recent systematic review and metaanalysis 175 . The interventions were delivered using several modalities, including home visits and telephone support, health care provision by professional and lay practitioners and individual and groupbased sessions, through multiple contact sessions and at postpartum initiation 174 .
The treatment of vulnerable women with anti depres sants for the prevention of depressive episodes or anxiety symptoms during the perinatal period has conflicting evidence 176 . One of the earliest studies demonstrated a reduction in the recurrence of postpartum major depres sion with prophylactic antidepressant treatment 177 . A small but emerging body of literature has suggested that hormonal therapies, light therapy and other forms of circadian manipulation are promising thera pies for the prevention of depression 178 . The use of hormonal thera pies, acupuncture, supplementation with ω3 PUFAs, light therapy or other forms of circadian manipu lation for the prevention of postpartum depression does not have strong supporting evidence 175, 178 .
Interventions for the prevention of postpartum psychosis include careful monitoring for symptom development in women at high risk and adjustments of prophylactic medication, especially in women with bipolar disorder 18, 24 . Prophylactic treatment dur ing pregnancy might reduce the rate of postpartum relapse in women with bipolar disorder, although no evidence from random ized controlled trials is avail able. For women with previous postpartum psychosis, prophy lactic treatment with lithium or antipsychotics immediately postpartum might reduce relapse 18 .
Management
The goals of treating mental illness in the postpartum period are to reduce maternal psychiatric symptoms and to support maternal-child and family functioning. All women and their families should receive education about the illness and the potential treatment options, including the potential benefits and harms of each treat ment. Social support should be optimized, and physi cal and psychiatric comorbidities should be addressed. In addition, strategies to assist women in obtaining sleep and a stable circadian rhythm are helpful, given that sleep deprivation is common during the postpartum period. In many cases, the symptoms of PPDs influence maternal-child interactions, which should be observed and discussed in a nonjudgemental way.
Although the specific recommended treatments depend on the underlying diagnosis, in general, a steppedcare approach is advocated, in which the intensity of the intervention matches the severity and acuity of the clinical presentation. For example, women with mild symptoms of depressive, anxiety, obsessivecompulsive and/or trauma and stressor related dis orders should first be offered the lowest intensity interventions, such as peer support and guided self help, whereas women who do not respond to these treatments might require formal psychotherapeutic interventions, such as psychological therapies. For women with severe symptoms, women who do not respond to non pharmacological treatment, or women who have bipolar disorder or psychosis, pharmaco logical interventions are likely to be introduced as a firstline treatment, used alone or in combination with a lower intensity intervention. In such cases, the bene fits of breastfeeding for the infant must be considered in the context of maternal mental wellbeing, the passage . This approach acknowledges that there might be several contextual factors contributing to false-negative mental health screening results.
of psychotropic medication into breast milk and the infant and the potential effects of medications on the neonate. Indeed, when breastfeeding is challenging and/or when frequent nighttime feedings lead to sleep disruption, symptoms of depression or anxiety might be precipitated or exacerbated. In these cases, the bene fits of breastfeeding must be weighed against the risk of ongoing maternal mental illness, and formula feeding is a viable and often recommended alternative. Other somatic treatments, such as electro convulsive therapy (ECT), can be considered in women with treatment refractory disorders. Throughout treatment, monitor ing progress to determine when or if to move to a higher intensity intervention and to ensure the safety of mother and child is important. In the initial assess ment and during treatment, the patient and her family should be asked whether thoughts of suicide or infanti cide have occurred. Safety concerns and/or evidence of active psycho sis are medical emergencies that require specialist consultation, emergency hospitalization and treatment.
Mood disorders and anxiety
Treatment of postpartum depression and other non psychotic mental disorders (such as anxiety, OCD and trauma and stressorrelated disorders; BOX 4) depends on the severity of the initial presentation and the level of functional impairment, including the effect on the maternal-child interaction 128 . For women with a past history of mental illness, the previous treatment response and the time to response of previous episodes should be considered. The patient's treatment prefer ence, in addition to access to care and utilization of care, should also be considered in all women, as patients who receive their preferred treatment are most likely to benefit from this treatment than other treatments 179 . Most women with nonpsychotic mental disorders often prefer psychotherapy over pharmacological treatments, although the uptake and effectiveness of this therapy can be limited owing to barriers in attending appointments, such as unpredictable infant schedules and competing childcare responsibilities 180 . Similarly, fathers also pre fer psychological treatments over pharmacological ther apy 181 . However, some women prefer pharmacological treatment alone; thus, individualizing treatments based on patient preferences is important. Treating maternal postpartum depression might not always improve the maternal-infant relationship, and additional inter ventions aimed at the mother-infant dyad or the family as a whole might be required 182 .
Psychological interventions.
Most trials for post partum depression have focused on nonpharmacological treat ments. For women with mild postpartum depression, psychosocial treatments, including peer support, guided selfhelp and supportive counselling by trained pro fessionals such as public health nurses (at home or in support groups), can improve symptoms. For example, one systematic review of five trials demonstrated a 1year remission rate of 68% in women with post partum depression who received psychosocial treat ments compared with a remission rate of 54% in women treated with standard primary care 138 . For women with moder ate symptoms of depression or women who do not respond to psychosocial strategies, psychothera pies such as CBT and IPT that specifically address the psychological and related challenges of transitioning to parenthood are effective when delivered in individual, group and partnerassisted formats and in person, by telephone or online 183 . A systematic review of four CBT trials and one IPT trial demonstrated a pooled remis sion rate of 60.3% for these interventions compared with a rate of 48.1% for usual care 138 . A CBTbased programme was demonstrated to reduce worry and depressive symptoms in women with postpartum anxiety disorders, such as GAD and social phobia, and OCD 184 . The effectiveness of CBT for postnatal OCD symptoms was confirmed in a small ran domized controlled trial 185 . Although additional research is required, CBTbased interventions for post partum anxiety disorders, and specifically interventions such as eye movement desensitization and reprocessing and traumafocused CBT for trauma and stressor related disorders, can be used, although the latter two interventions have not been specifically evaluated in postpartum women 186 . The increasing use of internetbased CBT and the development of mobile apps for this treatment modality demonstrate the power of digital health, which is often more accessible than traditional psychotherapy, and extends to individuals who cannot participate in psycho therapy. A good example of this is MumMoodBooster, which was developed in Australia 171 . Drug therapies. Antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors (SNRIs), are the mainstay of pharmacological treatment for post partum anxiety and depressive disorders. These therapies can be used alone or in combination with psychosocial or psychological treatments. In a systematic review,
Box 4 | General management guidelines for non-psychotic psychiatric disorders
• Identify somatic comorbidities and optimize their management.
• Check the mode of delivery, whether complications were present and whether delivery was experienced as traumatic. In the case of post-traumatic stress symptoms, consider specific treatments.
• Assess for suicidal thoughts and intrusive thoughts of harm towards the baby.
Consider the safety of the baby and whether the mother can provide care for the baby if she is alone or whether other adult supervision is required.
• Ask the mother about her attitude towards her baby and observe maternal-child interactions. Consider specific treatments with signs of problematic interactions or bonding.
• Review the feeding pattern of the baby. Address problems with breastfeeding or bottle feeding.
• Provide strategies to preserve sleep, such as finding another person to feed the infant at night. • Assess psychiatric history before starting treatment. Review the nature and effectiveness of past treatments and restart previous effective treatment when appropriate.
the pooled remission rate was significantly higher in patients receiving SSRIs (46.0%) than in those receiving placebo (25.7%) 187 . Although pharmacological therapies can be used alone or in combination with psychosocial or psycho logical treatments, whether combinatorial therapy is superior to either one alone has not been evaluated in postpartum women. However, combinator ial treatment does not lead to further improvements in functional outcomes compared with medication alone outside the perinatal period 188, 189 . To our knowledge, no drug treatment trials for maternal anxiety dis orders or for paternal postpartum depression or anxiety have been carried out. However, SSRIs and SNRIs are firstline pharmacological treatments for anxiety and depression outside of the postpartum period. The dur ation of antidepressant therapy required for newonset postpartum depression, anxiety or a related disorder has not been studied, but clinicians are recommended to follow guidelines for these disorders in the gen eral population. For depression, the initial treatment should be continued for 6 months to 1 year after remis sion; longer durations are required for severe and/or recurrent illness 190 . Many women and their partners are concerned about the safety of using antidepressants during breastfeeding. However, the use of antidepressants during the post partum period is not a contraindication to breastfeeding, and indeed, the avoidance of medication when needed for severe illness is associated with maternal suicides 191 . The passage of SSRIs and SNRIs into breast milk varies between drugs, but most pass into breast milk at <10% of the maternal dose, which is compatible with breast feeding 192 . As such, changing the antidepressant drug or the dose to switch to a drug with lower breast milk passage during the perinatal period is generally not recommended. For newonset postpartum depres sion, sertraline is often recommended as a firstline pharmaco logical treatment owing to its very min imal passage into breast milk (FIG. 2) . However, in patients with a prior history of psychiatric disorders, therapies that have previously shown efficacy should be consid ered, even those that have less data regarding safety dur ing breastfeeding. Other SSRIs, SNRIs or mirtazapine (an atypical antidepressant) also have minimal passage into breast milk, and therefore, these drugs are unlikely to be a cause for concern. Buproprion is generally not given to lactating women owing to case reports of infant seizures associated with exposure to this drug 193 . In cases of severe depression and/or anxiety (with or without psychotic features), older antidepressants and/or other therapies, such as benzodiazepines or antipsychotics, might be indicated.
Other treatments. Given the likely role of hormonal fluctuations in the aetiology of postpartum depression, hormonal treatments have been evaluated. Transdermal oestrogen therapy reduced the symptoms of post partum depression in one small study, but further trials are required. Progestin therapy worsened postpartum depressive symptoms 194 . One trial demonstrated the superiority of allopregnanolone to placebo in improv ing depressive symptoms in 21 women with severe 195 . However, using aerobic exercise for post partum depression was recently examined in a system atic review and has good supporting evidence for mild symptomatology 196 . ECT can be considered in severe or treatmentrefractory cases of depression.
Postpartum psychosis
Fluctuations in symptoms are common in women with postpartum psychosis, and thoughts of infanti cide or suicide are often well hidden. Thus, outpatient treatment is not safe, and psychiatric hospitalization is recom mended for diagnostic evaluation and treat ment 15 . The preferred treatment setting is a motherinfant joint admission unit, but these units are not available worldwide 197, 198 . Alternatives are the admis sion of the mother only to a hospital with expertise in perinatal psychiatric care or women's mental health, admission to a standard mental health inpatient setting if these facilities are unavailable, or, based on a care ful assessment of the safety of both the mother and the infant, intensive home treatment where available and with appropriate supervision 16 . The effect of these approaches on longterm outcomes of the mother and baby is being investigated 15 . The management of postpartum psychosis is depen dent on psychiatric history. For women with known severe psychiatric illness with nonperinatal episodes, reviewing the nature and effectiveness of past treat ments and restarting previous effective treatment are important. Management of women without a history of bipolar disorder or other severe psychiatric dis order is summarized in FIG. 2 . The main treatment goals for women without a prior history of bipolar disorder, psychosis or other severe psychiatric disorder include the limitation of the current episode and the preven tion of a bipolar disease course with multiple episodes. Accordingly, management in the first year post partum should focus on full recovery (that is, complete symp tom remission and social and vocational function ing). In the absence of guidelines and controlled trials, treatment recommendations are based on results from natur alistic cohort studies and expert consensus groups 24, 199 . The largest study (consisting of 68 patients) demonstrated the efficacy of a stepwise sequence of shortterm benzodiazepines, antipsychotics and lithium and showed remission in 98.4% of patients in the acute phase 200 . Moreover, this study demonstrated that lithium monotherapy is protective against relapse of psychosis, depression and mania within 1 year. The secondlargest study described successful ECT treatment in 34 patients with postpartum psychosis of whom many had symp toms of catatonia 201 . The effectiveness of lithium and ECT is supported by case reports 202 . Successful treat ment with antipsychotics has been described in case reports 203, 204 , but antipsychotic monotherapy did not show efficacy in a cohort study 200 . In general, lithium monotherapy might be the preferred initial intervention for postpartum psychosis, but adjunctive treatment with benzodiazepines or antipsychotics is useful for the acute treatment of agitation, mania and psychotic symptoms, given the welldocumented effectiveness in non perinatal populations. Several antipsychotics are used for the treatment of severe PPDs, including risperidone, quetiapine and olanzapine 205 . ECT is the primary treat ment for patients with severe catatonic or depressed psychotic features or if patients prefer this therapy 15 . Anticonvulsants (that is, antiepileptic medications) are used less frequently during the perinatal period as mood stabilizers for the treatment of bipolar disorder because of concerns of teratogenicity. Valproate use dur ing pregnancy and lactation is associated with neural tube defects and neurocognitive developmental delays in offspring 24, 206 . Thus, valproate use is not advised during the perinatal period, unless the risk-benefit assessment determines a prior efficacy in particular women. By con trast, lamotrigine is used for the treatment of bipolar depression (not bipolar mania) and is not associated with an increased risk of congenital malformations in offspring 207 . A review of recent studies demonstrated that lamotrigine had no adverse outcomes on infant IQ or neurodevelopment 208 . The management of a breastfeeding woman with a severe psychiatric episode is challenging owing to con cerns about the exposure of breastmilk to pharmaco logical therapies and the need for sleep preservation in the mother 15 . The use of lactation inhibitors should be avoided. In some countries, the mother is recommended to breastfeed only if extensive psychiatric support and access to a paediatric professional who can monitor the infant are available. Moreover, the mother and her partner should be educated about the risks of breast feeding with pharmacotherapy. In other countries, a more individualized approach (for example, NICE guidelines) based on previous responses to medication, preferences regarding breastfeeding and psychopatho logy 24 , other than avoidance of breastfeeding if lithium (rather than an antipsychotic) is used, can be applied. Small case series have provided information regarding the safety of lithium in lactation 209, 210 . When possible, levels of lithium in the infant's serum should be closely monitored; on average, the serum level of lithium is 25% of the maternal levels, but the range can vary, and dehydra tion can lead to toxic levels 15, 210 . No adverse effects were reported in ten infants of breastfeeding mothers who received ECT 201 .
Quality of life
The symptoms and morbidity of postpartum depression are often reported in the academic literature, but this offers only a rather constricted view of the quality of life (QOL) of women with PPDs 125, 211, 212 . Nevertheless, the classic core symptoms of a depressive disorder would be expected to decrease the subjective quality of both an individual's inner life experience (anhedonia, sadness, hopelessness and thoughts of death) and their function ing (psychomotor retardation or agitation and disturbed sleep). Anxiety is frequently comorbid, and this further influences QOL with persistent worry symptoms.
The definitions vary, but QOL is a broader multi dimensional construct that commonly incorporates two central aspects: emotional wellbeing (including frequency and intensity of joy, sadness and affection) and life evaluation (how satisfied one is with one's life, for example, housing and employment). Health and the ability to function as an essential component of QOL are referred to as healthrelated QOL (HRQOL). Mater nal QOL during the postpartum period also affects her infant's current and future QOL. Many mothers with postpartum depression have difficulty interacting with their infants in a positive way 213 , exhibiting neg ative behaviours such as making less eye contact, show ing less synchronous responsiveness, being uninvol ved and showing restricted affect during mother-infant interactions [214] [215] [216] . Infant attachment security is a key predictor of child outcomes, including neurological, psychological and social outcomes over the course of development 217 . In addition, children of mothers with perinatal depression might have poorer psychological outcomes when they reach 18 years of age than the chil dren of mothers without perinatal depression 218 . Some women have an intrusive engagement style that might lead to longterm difficulties in child social, cognitive and behavioural domains 219 . Women with postpartum psychosis face even more parenting challenges, often including disrupted attachment, which affects the QOL of the mother and child 220 . One of the most widely used generic measures of QOL is the 36item shortform (SF36) 221, 222 , which has eight health domains that measure limitations in physical or usual role activities due to health issues, limitations in usual role or social activities due to emo tional issues, pain, mental health, vitality and general health perceptions. The SF36 has been used in over 1,000 publications and for over 130 disorders, includ ing those that occur during the postpartum period, and both the full and short versions of this scale have been validated by numerous studies 222, 223 . However, few measures of QOL have been developed specifi cally for use in the postpartum period 224 . Only three instruments for use during the postpartum period were reported in one systematic review 225 : the Mother Generated Index (MGI) 226 , the Maternal Postpartum QOL (MAPPQOL) Questionnaire 227 and the Rural Postpartum QOL (RPQOL) scale 228 . The MGI requires women to specify domains of their life that have been affected by the birth of their baby, either positively or negatively, and to then score these out of 10 (REF.
229
). The most common changes reported were tiredness, less personal time, less time with partners or other family members, a worse relationship with partners or other family members, physical complaints, low selfesteem, financial worries, negative feelings towards the baby, more housework, a poor sex life and a reduced sense of happiness or fulfilment 226 . Not surprisingly, people with depressive illness report lower scores on generic QOL and HRQOL measures, similar to women with postpartum depressed mood 230, 231 . Small studies in postpartum women also suggest that QOL is amenable to intervention. Improvements in QOL are not fully explained by improvements in the severity of depressive symp toms, suggesting that interventions should go beyond the mere reduction of symptom severity and consider other factors that contribute to QOL as targets for inter vention. Maternalspecific measures of QOL could be integrated into postpartum depression screening pro grammes or routine postnatal care 232, 233 . Indeed, QOL measures that allow a woman to identify which areas of her life are most important to her could be used to allow a woman to indicate where she would like to see improvements 226 . Emerging studies have highlighted the beneficial effect of social support on QOL 234 , in addi tion to risk factors for reduced QOL, such as younger age and lower socioeconomic status in women with postpartum depression 235 . PPDs have economic considerations and can affect qualityadjusted life years (QALYs) 141 . QALYs take into account how treatment affects quality and quantity of life, and accordingly, QOL measurement is neces sary for studies of costeffectiveness of treatments. Compelling data from the London School of Economics demonstrated the high economic costs of PPDs and the need to address the loss of QALYs of women and their children by the treatment and prevention of these dis orders 236 . This finding is particularly pertinent given the shortterm and longterm effects of postpartum depres sion. Indeed, as most women recover from postpartum mood disorders, these disorders can become chronic in a subgroup of women 237 . One study demonstrated that for each 1year cohort of births, perinatal depression, anxiety and psychosis cost the United Kingdom around £8.1 billion in the long term 236 .
Outlook
The postpartum period is a vulnerable time for the onset of psychiatric illness. Indeed, postpartum mood and anxiety are heterogeneous and might be trig gered by biopsychosocial factors, including a vulner ability to the robust endocrine and immunerelated changes that occur at childbirth. The heterogeneity of these disorders requires a thoughtful approach to assessment and treatment planning that includes the clinical presentation, family and personal psychiatric history, other psychosocial risk factors (including his tory of trauma) and awareness of potential bio logical or genetic contributions that might influence risk and vulnerability. The precise vulnerability that leads to some women developing PPDs is currently unknown, and novel research approaches are needed to identify the under lying pathophysiology of both prepartum and post partum anxiety, depression and psychosis. This will require a multifaceted approach in preclinical, clinical and translational research to determine the mech anisms behind the neurobiology and physio logical corre lates of PPDs and the observed peripartum mood and mothering behaviours. Additionally, these strategies must address the differences in the timing of symptom onset and the diverse types of symptoms in these disorders.
Given the morbidity and mortality of postpartum psychosis, episodes of psychosis might be best con sidered to represent women with a bipolar disorder diathesis with a puerperal trigger. Understanding this trigger will be beneficial and should allow the develop ment of new treatments and, ultimately, enable the prevention of psychosis or unfavourable outcomes in women at high risk. Effective evidencebased treatment approaches are available for psychosis and depression, including psycho pharmacology, psychotherapy, ECT and circadian manipulation. However, postpartum depression and postpartum psychosis require differ ent and targeted treatment approaches, and therefore, bipolarity must be considered in the evaluation and management of all women with postpartum mood and anxiety disorders. In addition, primary treatment goals should include the limitations of the current epi sode and the prevention of future episodes (including unipolar or bipolar disease with multiple episodes and chronic anxiety). Whether a continuum of sever ity between postpartum depression and postpartum psychosis exists, or whether these disorders represent different conditions with different aetiological factors, requires further study.
A potential barrier to the engagement and retention of women for the treatment of postpartum mood dis orders is stigma. Understanding this stigma and the fear that women have regarding postpartum mood dis orders is essential. The voices of women with postpartum mood disorders must be incorporated into the develop ment of services to ensure that the needs of women, their infants and families are met 238, 239 . To date, the amount of research provides an impor tant road map for PPDs in general, and guidelines for screening or identification and treatment for perinatal depression in many countries give a strong mandate to improve mental health care for all women in the peri natal period. Thus, developing effective strat egies in countries of all economic levels that allow the delivery of targeted therapies to women with different clin ical phenotypes and severities of PPDs is imperative. In addition, whether the current ICD10 and DSM5 classification systems are adequate for detecting specific phenotypes or diagnostic groups of patients should be evaluated. We should also consider that PPDs might be phenotypically different than psychiatric dis orders that begin during pregnancy. Indeed, disorders that occur postpartum might have unique character istics in epidemiology, pathophysiology, psychosocial contributions, prevention and management.
In summary, PPDs are morbid and costly dis orders. Advocating for early identification and screening that begins in pregnancy to identify women at risk, in addi tion to timely and effective treatment of PPDs, is essen tial. Given the recent advances in knowledge, this is an incredibly exciting time for research in perinatal mood disorders. New approaches might allow the identifica tion of the underlying causes of postpartum mood dis orders, which could lead efforts to identify women at risk and personalize treatment. Although genetic, bio logical and hormonal signals likely have an important role in the risk of these disorders, psychosocial contrib utions, including the effect of lifetime stressors, must be part of a comprehensive workup and treatment plan. The social determinants of postpartum mood disorders, such as poverty, domestic violence, poor housing and insecure migration status, should also be assessed as part of routine practice in maternal health care for all women. Finally, we must recognize that maternal mental health is necessary for the physical and mental health of mothers, infants and families 17 and that advocating and protecting this population is our obligation.
